[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsonism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsonism":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,73,102,125,146,175,208,228,260,286],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644726","cross-system-effects-of-acute-intermittent-hypercapnia-based-interventions-in-pd-100644726",false,"NCT07674264","Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD","A Pilot Study of Acute Intermittent Hypercapnia-Based Interventions on Upper Airway and Axial Motor Function in Parkinson's Disease","Inclusion Criteria:\n\n1. adults 40 to 75 years of age (the latter to reduce the likelihood of cardiovascular disease)\n2. diagnosis of idiopathic Parkinsonism with Hoehn and Yahr stages 2-4\n3. medically stable with physician clearance\n4. ability to ambulate at least 10 feet with\u002Fwithout assistance\n5. ability to follow directions\n6. willing to abstain from blood donation for the duration of the study\n\nExclusion Criteria:\n\n1. additional neurologic conditions\n2. severe illness or infection, including respiratory\u002Fcardiovascular\u002Flung disease, or uncontrolled hypertension\n3. inspiratory stridor\n4. pregnancy due to unknown tAIH effects on a fetus, although females of childbearing age will not be excluded\\*\n5. cigarette smoking or vaping within 5 years\n6. history of head\u002Fneck\u002Flung cancer with the exception of basal cell carcinoma\n7. is currently participating in another research study that could influence the results from this study\n8. has deep brain stimulation electrodes implanted or has a history of deep brain stimulation\n9. faints or becomes lightheaded at the sight of blood\n\n   * If a female of childbearing potential indicates there is a chance she could be pregnant, she will be provided a pregnancy test and allowed to continue in the study if negative. This is because the fetal risks associated with intermittent hypoxia are unknown.","ALL","40 Years","75 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) or hypercapnic normoxia (AIHN) improves upper airway and axial motor function in Parkinsonism, and explores biomarker correlates of intervention responsiveness.",[27,28],"Parkinson Disease","Parkinsonism",[30,31,32,33],"Axial function","Upper airway","Breathing","Acute Intermittent Hypercapnic Hypoxia","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":21},"2026-06-20",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"University of Florida","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100635527","a-multimodal-prospective-cohort-study-of-parkinsonism-100635527","NCT07553845","A Multimodal Prospective Cohort Study of Parkinsonism","Inclusion Criteria:\n\nFor participants with rapid eye movement sleep behavior disorder:\n\n* Meets the diagnostic criteria for rapid eye movement sleep behavior disorder established by the American Academy of Sleep Medicine\n* Chinese citizen\n* Age \\>30 years and \\\u003C80 years\n* Able to understand the study, show good compliance, and provide written informed consent personally or through a legal representative\n\nFor participants with Parkinsonism:\n\n* Meets the diagnostic criteria for Parkinsonism established by the International Parkinson and Movement Disorder Society\n* Chinese citizen\n* Age \\>30 years and \\\u003C80 years\n* Able to understand the study, show good compliance, and provide written informed consent personally or through a legal representative\n\nFor healthy controls:\n\n* No neurodegenerative disease, no history of head trauma or head surgery, no history of stroke, epilepsy, tumor, or psychiatric disease\n* No metal implants or cardiac pacemaker\n* No severe chronic disease or severe hepatic or renal insufficiency\n* Chinese citizen\n* Age \\>30 years and \\\u003C80 years\n* Education level of primary school or above\n* Able to understand the study, show good compliance, and provide written informed consent personally or through a legal representative\n\nExclusion Criteria:\n\n* Significant cognitive impairment (MMSE ≤23)\n* Unable to sign the informed consent form or unable to complete study procedures for other reasons\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for this study",true,"31 Years","79 Years",{"count":57,"type":21},640,"5 Years","OBSERVATIONAL","This is a single-center, prospective, observational cohort study designed to investigate the progression and differential diagnosis of Parkinsonism using a multimodal approach. The study plans to enroll 400 patients with Parkinsonism, 120 patients with rapid eye movement sleep behavior disorder, and 120 healthy controls, with follow-up for 5 years.\n\nAssessments will include neuroimaging, clinical rating scales, biological samples, blood flow evaluation, neurophysiological testing, tremor analysis, and voice and video assessments. The study aims to characterize disease progression, explore factors associated with progression from rapid eye movement sleep behavior disorder to Parkinsonism, and improve the ability to distinguish among different Parkinsonian disorders.",[28,62],"REM Sleep Behavior Disorder","2026-04-20",{"date":65,"type":38},"2026-04-28",{"date":67,"type":38},"2024-05-01",{"date":69,"type":21},"2029-05",{"name":71,"class":45},"Ruijin Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":84,"studyType":59,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":72},"100622622","etiology-phenotype-outcome-pathway-study-on-freezing-of-gait-fog-100622622","NCT07386015","Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","FREEZE-Path Cohort: Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","Inclusion Criteria:\n\n1. Age 30-85 years\n2. Presence of freezing of gait or non-freezing gait or balance impairment\n3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus)\n4. Ability to complete gait and balance assessment tasks independently or with assistance\n5. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe dementia (Mini-Mental State Examination score \\\u003C 10)\n2. Severe psychiatric disorders interfering with study participation\n3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety\n4. Stroke, fracture, or other major medical events within the past 3 months\n5. Inability to comply with follow-up procedures\n6. Refusal of video or speech data collection","30 Years","85 Years",{"count":83,"type":21},700,"36 Months","This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.",[87,88,28,89,90],"Freezing of Gait","Parkinson's Disease","Vascular Parkinsonism","Idiopathic Normal Pressure Hydrocephalus (INPH)",[87,88,92],"parkinsonism","2026-03-08",{"date":95,"type":38},"2026-03-10",{"date":97,"type":38},"2026-02-28",{"date":99,"type":21},"2030-11-30",{"name":101,"class":45},"Tianjin Huanhu Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":53,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":72},"100626956","the-effect-of-functional-rotational-exercises-on-fall-risk-and-mobility-in-parkinsons-disease-patients-100626956","NCT07442370","The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients","The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients: A Randomized Controlled Study","Inclusion Criteria\n\n* Individuals with a clinical diagnosis of idiopathic Parkinson's disease (Hoehn \\& Yahr stages 1-2)\n* Individuals aged 50-70 years\n* Mini Mental State Test score ≥ 24\n* Individuals whose medical treatment has been stable in the last 6 weeks\n* Individuals with stable vital signs\n* Individuals who volunteer to participate in the study and understand the purpose and process of the study, and who have signed a written informed consent form\n\nExclusion Criteria\n\n* Advanced Parkinson's disease (H\\&Y 3-5)\n* Severe orthopedic problems\n* Vestibular system disorders\n* History of serious falls in the last 6 months","50 Years","70 Years",{"count":112,"type":21},50,[24],"This study aims to contribute to clinical applications by investigating the effectiveness of functional rotation exercises on fall risk, mobility, and balance in patients diagnosed with idiopathic Parkinson's disease.",[27,28],"2026-03-02",{"date":118,"type":38},"2026-03-03",{"date":120,"type":38},"2026-03-01",{"date":122,"type":21},"2026-09-15",{"name":124,"class":45},"Uskudar University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":72},"100617733","the-effect-of-spinal-cord-stimulation-on-orthostatic-hypotension-in-parkinsonism-and-its-related-mechanisms-100617733","NCT07322458","The Effect of Spinal Cord Stimulation on Orthostatic Hypotension in Parkinsonism and Its Related Mechanisms","Inclusion Criteria:\n\n* 1\\. Aged between 40 and 80 years;\n* 2\\. No dementia as measured by the cMMSE scale (formal cMMSE score should be \\>20 for subjects with 1 to 6 years of formal education; cMMSE score should be \\>24 for subjects with \\>6 years of formal education);\n* 3\\. Able and willing to follow instruction of the researcher;\n* 4\\. No other conditions that the researchers consider inappropriate for inclusion:\n\nExclusion Criteria:\n\n* 1\\. Severe depression (HAMD-17 above 17 as moderate to severe) or anxiety;\n* 2\\. Pregnancy;\n* 3\\. History of alcoholism;\n* 4\\. No skin abnormalities;\n* 5\\. Non-neurological disease-related symptoms that prevent patients from participation in the study.","80 Years",{"count":133,"type":21},40,[24],"Parkinson's disease (PDS) is a syndrome characterized by tremor, bradykinesia, rigidity, and postural disturbances. Causes include Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). Non-motor symptoms of PDS, such as neurogenic orthostatic hypotension (nOH), have received more intensive research due to their greater disabling potential compared to motor symptoms. In patients with PD and MSA, nOH can lead to intolerance to medications such as levodopa, significantly increasing the risk of falls, accelerating cognitive decline, and increasing the risk of all-cause mortality. However, conventional pharmacological treatments (such as midodrine, droxidopa, and fludrocortisone) and non-pharmacological approaches (such as compression abdominal bands, elastic stockings, and deep brain stimulation) for non-motor symptoms such as nOH have numerous limitations, including short-term efficacy, uncertain efficacy, and side effects. Therefore, exploring new non-pharmacological treatments to improve nOH and delay disease progression in patients with PDS is crucial for improving their quality of life and prognosis.\n\nSpinal cord stimulation (SCS), including invasive (epidural) spinal cord stimulation (eSCS) and non-invasive (transcutaneous) spinal cord stimulation (tSCS), is a novel neuromodulatory technique with clinical applications in a variety of neurological diseases. Currently, several small-sample studies have suggested the potential efficacy of SCS for nOH caused by spinal cord injury (SCI). This study innovatively proposes the use of eSCS and tSCS to improve nOH and related clinical symptoms in patients with PDS. A prospective, single-center, randomized, controlled clinical trial is planned to compare the efficacy of invasive and non-invasive SCS in treating nOH, thereby providing new insights for the effective treatment of PDS.",[28],"NOT_YET_RECRUITING","2026-01-07",{"date":140,"type":38},"2026-01-09",{"date":142,"type":21},"2026-01-01",{"date":144,"type":21},"2028-06-30",{"name":71,"class":45},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":72},"100608864","observational-case-series-of-patients-with-parkinsons-disease-pd-attending-a-complementary-medicine-neuro-degenerative-disease-ndd-clinic-100608864","NCT07207096","Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.","Inclusion Criteria: A diagnosis of Parkinson's Disease (self-reported), and Parkinsonism from any causes (patients may have co-existing other health conditions)\n\nExclusion Criteria: Patients requiring acute medical assessment and management, (as this is beyond the scope of this clinic service) Patients with any other NDD condition Patients without a diagnosis of PD\u002FParkinsonism. E.g. those at risk of PD such as through a family history (patients in this category may receive treatment at the clinic but are not included in the Observational Case series.","18 Years",{"count":154,"type":21},100,"When the charity Homeopathy UK launched a new London based charitable clinic for Neurodegenerative Diseases (NDD), including Parkinson's Disease (PD), it was considered important to document patient's experiences of a high-quality complementary medicine clinic, to enable a greater understanding of the role of complementary medicine for PD.\n\nRoutine clinical data, including a couple of questionnaires, is collected from consecutive patients with PD seen in the NDD clinic. Treatments provided are complementary to patients' usual medical treatment, and include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition. Consultations take place approximately every 3 months and patients complete questionnaires at the time of each consultation.",[27,28],[158,159,160,161,162,163,164,165,27],"homeopathy","herbalism","hypnosis","healing","complementary medicine","lifestyle","self-help","mindfulness","2025-09-26",{"date":168,"type":38},"2025-10-03",{"date":170,"type":38},"2025-09-19",{"date":172,"type":21},"2027-08-31",{"name":174,"class":45},"St. Mary's University, Twickenham",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":186,"studyType":59,"phases":4,"briefSummary":187,"conditions":188,"keywords":193,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100582886","saliva-and-extracellular-vesicles-for-neurodegenerative-diseases-100582886","NCT06869135","Saliva and Extracellular Vesicles for Neurodegenerative Diseases","Novel Method for Diagnosis of Neurodegenerative Diseases Based on Saliva Biochemical Profiling","MINERVA","Inclusion Criteria:\n\n* AD: standard criteria for dementia due to AD with AD neurochemical demonstration.\n* PD: MDS Criteria; modified Hoehn\\&Yahr stages; stable pharmacological treatment (last 4 weeks).\n* AtP: current consensus diagnostic criteria for progressive supranuclear palsy; corticobasal degeneration and multiple system atrophy.\n* prodromic PD: according to diagnostic criteria by Berg;\n* MCI: according to diagnostic criteria by Dubois and Albert.\n\nExclusion Criteria:\n\n* For all the experimental groups considered, subjects with concomitant chronic and \u002F or inflammatory diseases of the oral cavity, other systemic diseases, oncological or infectious diseases will be excluded.\n* Patients not able to provide written informed consent autonomously will be excluded.\n* For PD patients: Vascular, familiar and drug- induced parkinsonism, other known or suspected causes (metabolic, brain tumor etc) or any suggestive features of AtP; dementia with MoCA Test Correct Score\\\u003C15","45 Years",{"count":185,"type":21},242,"12 Months","Early diagnosis of Neurodegenerative diseases (NDDs) and accurate patient profiling are key goals needed to tailor prompt personalized therapeutic strategies that can significantly impact disease progression and patients' quality of life. The project will validate a novel, cost-effective and quick biophotonic-based method for early and differential diagnosis of NDDs (Parkinson's disease, atypical parkinsonisms, Alzheimer's disease) and for routine clinical monitoring of NDD progression (longitudinal study). Raman spectroscopy (RS) will be applied to biochemically profile saliva and salivaderived Extracellular Vesicles (sEVs) and to identify a spectroscopic biomarker for NDDs. Optimized protocols for RS will be used to concomitantly evaluate saliva and sEVs from people with NDDs and to detect salivary changes in the biochemical profile, with special focus on EV-associated components. The accuracy of the method in discriminating NDDs at different disease stages and during disease progression will be verified. A nanotechnology-based biomolecular characterization of saliva and sEV will clarify the involvement of specific pathological molecules in NDDs progression.",[189,27,190,28,191,192],"Neurodegenerative Diseases","Alzheimer Disease","Mild Cognitive Impairment (MCI)","Prodromal Parkinson's Disease",[194,195,196,197],"Saliva","Raman Spectroscopy","Extracellular Vesicles","Diagnosis","2025-08-04",{"date":200,"type":38},"2025-08-07",{"date":202,"type":38},"2025-01-24",{"date":204,"type":21},"2027-12-15",{"name":206,"class":45},"Fondazione Don Carlo Gnocchi Onlus",5,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":131,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":72},"100452415","spinal-cord-stimulation-for-parkinsonism-100452415","NCT05171205","Spinal Cord Stimulation for Parkinsonism","Spinal Cord Stimulation for Parkinsonism: a Single-center, Single-arm Open Trial","SCS for PDS","Inclusion criteria:\n\n1. Diagnosed with parkinsonism according to MDS clinical diagnostic criteria for Parkinson's disease\n2. Aged between 50 and 80 years\n3. Able and willing to follow instruction of the researcher\n4. No other conditions that the researchers consider inappropriate for inclusion\n\nExclusion criteria:\n\n1. Severe depression (HAMD-17 above 17 as moderate to severe) or anxiety\n2. Pregnancy\n3. History of alcoholism\n4. Non-neurological disease-related symptoms that prevent patients from participation in the study",{"count":112,"type":21},[24],"Spinal Cord Stimulation (SCS) is a newly emerged neuromodulation technique in recent years. It is now a mature technique in the treatment of chronic pain and is generally accepted by patients because of its non-destructive and reversible nature, few complications, no side effects, and avoidance of unnecessary surgical procedures. Combining the results of previous studies and the group's previous research, this study first proposes an innovative treatment protocol for PDS with SCS. We intend to conduct a prospective single-center open clinical trial to evaluate the improvement of orthostatic hypotension, urinary retention, sleep disturbance, dysarthria, and dysphagia in Parkinsonism (PDS) patients before and after SCS treatment, and shed new light on the treatment for PDS.",[28],"2025-05-05",{"date":222,"type":38},"2025-05-09",{"date":224,"type":38},"2021-05-01",{"date":226,"type":21},"2026-12-31",{"name":71,"class":45},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":238,"conditions":239,"keywords":247,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":72},"100224095","modifiable-variables-in-parkinsonism-mvp-100224095","NCT02194816","Modifiable Variables in Parkinsonism (MVP)","Modifiable Variables in Parkinsonism (MVP) [Formerly CAM Care in PD]","Inclusion Criteria:\n\n* Parkinson's disease (PD)\n* Parkinsonism\n* Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)\n* Must have online access, an email address, basic computer literacy\n* Must be willing to complete online surveys every 6 months for 5 years\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite English\n* Inability or unwillingness to complete surveys every six (6) months (\\~90 min)","19 Years",{"count":237,"type":21},2000,"We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.",[88,28,240,241,242,243,244,245,246],"MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","Shy-Drager Syndrome","Corticobasal Degeneration","Dementia With Lewy Bodies","Pick Disease","Olivopontocerebellar Atrophies",[88,248,249,250],"PD","Complementary and Alternative","CAM","2022-03-10",{"date":253,"type":38},"2022-03-25",{"date":255,"type":4},"2012-09",{"date":257,"type":21},"2030-12",{"name":259,"class":45},"Bastyr University",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":53,"sex":16,"minAge":267,"maxAge":4,"enrollmentInfo":268,"targetDuration":269,"studyType":59,"phases":4,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":46},"100267383","parkinsons-families-project-100267383","NCT02760108","Parkinson's Families Project","PFP","Inclusion Criteria:\n\nClinical diagnosis of Parkinson's disease or parkinsonism, and either family history of Parkinson's\u002Fparkinsonism (first or second degree family member affected by Parkinson's or parkinsonism) AND\u002FOR Early onset Parkinson's\u002Fparkinsonism (symptom onset before the age of 45 years) First or second degree family member of an Index Case, affected or unaffected by Parkinson's\u002Fparkinsonism.\n\nAged over 16 years\n\nExclusion Criteria:\n\nLack of capacity to consent to participate in the project.","16 Years",{"count":237,"type":21},"1 Month","One person in every 500 has Parkinson's and around 127,000 people are living with the condition in the UK. The aim of the study is to identify new genes that predispose or cause Parkinson's Disease or Parkinsonism. There is a pressing need to study the genetic makeup of family members both with and without Parkinson's. As families share a common genetic background, it is easier to find new Parkinson's genes by studying the genetic makeup of people with Parkinson's alongside other members of their families. We are particularly interested in studying the genetic makeup of two groups of people:\n\n1. those who developed Parkinson's before the age of 45; and\n2. those who have a family history of other relatives affected by Parkinson's.\n\nBy identifying genetic factors that cause Parkinson's, we hope to understand more about the condition. Doing so will lead to the development of better diagnosis, improved disease models, and we hope in time, to the development of better treatment.",[88,28],[273,274,275,276],"Early onset Parkinson's disease","Familial Parkinson's disease","Parkinson's disease","Genetics","2019-06-10",{"date":279,"type":38},"2019-06-12",{"date":281,"type":4},"2015-04",{"date":283,"type":21},"2027-01",{"name":285,"class":45},"University College, London",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":18,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":297,"conditions":298,"keywords":303,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":72},"100323751","phase-4-smoking-cessation-with-varenicline-in-schizophrenia-antipsychotic-induced-neurological-symptoms-as-correlates-100323751","NCT03495024","Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates","Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response","Inclusion Criteria:\n\n* DSM 5 criteria for schizophrenia or schizoaffective disorder and stable disease\n* Glazer-Morgenstern-Doucette criteria for TD\n* Smoking at least 5 cigarettes on average daily for at least 30 days prior to screening\n* An exhaled carbon monoxide concentration greater than 5 parts per million (ppm) at screening\n* Agree to stop smoking by the target date (four weeks after baseline\n* Concurrence for varenicline treatment from the patient's mental health provider if the patient is under mental health care; OR, if the patient is not under mental health care, the prescribing clinician should consult with a mental health provider to evaluate the patient for appropriateness to receive varenicline\n\nExclusion Criteria:\n\n* Have untreated or unstable acute medical or psychiatric illnesses\n* Have a history of seizures\n* History of somnambulism\n* Have chronic degenerative neurological illnesses (e.g., Parkinson's disease)\n* Have a history of active substance abuse (including marijuana abuse) in the 3 months prior to screening or a positive toxicology screen\n* Are receiving clozapine or cholinesterase inhibitors\n* Had a change in dosing or medication type of antipsychotic or anti-muscarinic for one month prior to enrollment (two months for long-acting antipsychotics)\n* Are unable to remain on a stable dose of antipsychotic or anti-muscarinic during the study period\n* Have acute suicidal ideation, intent or behavior within 12 months or risk based assessed on the C-SSRS or depression\u002Fanxiety score ≥ 8 on the HADS.\n* Female subjects of childbearing age will have a negative pregnancy serum test at screening and are required to use approved methods of birth control\n* Use of an investigational drug within 30 days of screening\n* Use of other smoking cessation aids (bupropion, nicotine replacement products)\n* Use of other tobacco products\n* History of allergic reactions to varenicline\n* Lack capacity to provide informed consent",{"count":294,"type":21},10,[296],"PHASE4","To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using standardized rating scales. The aim is to examine clinically significant effects on antipsychotic-induced neurological side effects that may warrant further investigation.",[299,300,301,302,28],"Schizophrenia","Schizoaffective Disorder","Tobacco Smoking","Tardive Dyskinesia",[299,304,305,306,307,28],"Schizoaffective disorder","Antipsychotics","Tobacco smoking","Tardive dyskinesia","2019-03-20",{"date":310,"type":38},"2019-03-22",{"date":312,"type":38},"2019-01-01",{"date":314,"type":21},"2020-06-30",{"name":316,"class":317},"Corporal Michael J. Crescenz VA Medical Center","FED"]